Emergent BioSolutions Secures $56 Million U.S. Government Contract for Smallpox and Mpox Vaccine
Emergent BioSolutions Inc. has announced a $56 million contract modification with the U.S. government for the supply of its ACAM2000® vaccine, intended for smallpox and mpox immunization. Deliveries are slated to begin this month, bringing projected annual sales for the vaccine and related products to over $120 million. The contract reflects the ongoing collaboration between Emergent and the government to enhance public health preparedness. ACAM2000® is a single-dose vaccine, approved by the FDA for individuals at high risk of smallpox and mpox infection, and is stockpiled both in the U.S. and internationally. This agreement is part of Emergent's existing 10-year contract with the U.S. Department of Health and Human Services.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emergent BioSolutions Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001367644-25-000188), on September 11, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。